Quest Diagnostics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/18/2024
Quest Diagnostics Stock Forecast and Price Target
In recent months, eight notable analysts have provided yearlong price targets for Quest Diagnostics, with the average target coming in at $145.00. If it were to be achieved, this would result in a potential upside of approximately 0.46 percent from the most recent closing price in May, 2024. The high end is $160.00, and the low is $136.00. If you want to buy DGX stock, it might be a good idea to look at its competitors too.
0.46% Upside
Quest Diagnostics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Quest Diagnostics's Price has fallen from $156.07 to $0.00 – a 100.00% decrease. Next year, analysts are expecting Fair Value to reach $126.20 – an increase of 100.00%. Over the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$770.00 | Buy/Sell | $636.99 | 13.96% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF237.10 | Buy/Sell | CHF307.83 | 14.93% |
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF93.37 | Buy/Sell | CHF105.00 | 15.26% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$265.80 | Buy/Sell | $260.33 | 2.49% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$104.09 | Buy/Sell | $118.92 | 21.53% |
Quest Diagnostics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Quest Diagnostics's Revenue has fallen from $9.44B to $9.25B – a 1.96% decrease. Next year, analysts are expecting Revenue to reach $9.38B – an increase of 1.43%. Over the next seven years, the forecast is for Revenue to grow by 6.53%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$28.64 | Buy/Sell | $32.87 | 6.49% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.75 | Buy/Sell | £17.30 | 12.39% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$236.30 | Buy/Sell | $284.47 | 17.44% |
.jpg)
Quest Diagnostics Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Quest Diagnostics's Dividend per Share has grown by 26.79%, rising from $2.24 to $2.84. In the following year, 7 experts forecast Quest Diagnostics's Dividend per Share will decrease by 4.93%, to $2.70. Over the next seven years, experts predict that Quest Diagnostics's Dividend per Share will grow at a rate of 0.79%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.53k | Buy/Sell | ¥5.24k | 7.58% |
| IQV Stock Forecast | IQVIA Holdings | Outperform |
15
|
$231.18 | Buy/Sell | $267.27 | 18.95% |
| BAYN Stock Forecast | Bayer | Hold |
5
|
28.58€ | Buy/Sell | 45.15€ | 4.97% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ICLR Stock Forecast | ICON Public | Buy |
16
|
$314.72 | Buy/Sell | $306.07 | 14.39% |
| 7751 Stock Forecast | Canon | Hold |
18
|
¥4.28k | Buy/Sell | ¥3.74k | -11.24% |
| LH Stock Forecast | Laboratory Corp of America Hol... | Outperform |
11
|
$210.59 | Buy/Sell | $241.28 | 14.92% |
Quest Diagnostics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Quest Diagnostics's EBITDA has gone down from $2.47B to $1.77B – a 28.16% drop. In the next year, analysts believe that EBITDA will reach $1.88B – an increase of 6.30%. For the next seven years, the forecast is for EBITDA to grow by 7.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$111.07 | Buy/Sell | $159.28 | 32.80% |
| HOLX Stock Forecast | Hologic | Outperform |
8
|
$75.02 | Buy/Sell | $81.06 | 12.64% |
| BVI Stock Forecast | Bureau Veritas | Outperform |
18
|
27.52€ | Buy/Sell | 26.96€ | 12.65% |
Quest Diagnostics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Quest Diagnostics's EBIT has fallen from $2.11B to $1.33B – a 36.69% decrease. In the next year, analysts believe that EBIT will reach $1.48B – an increase of 11.19%. For the next seven years, experts predict that Quest Diagnostics's EBIT will grow at a rate of 47.18%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIM Stock Forecast | bioMérieux | Outperform |
18
|
95.90€ | Buy/Sell | 105.55€ | 19.92% |
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.78k | Buy/Sell | ¥9.58k | 23.91% |
| ERF Stock Forecast | Eurofins Scientific | Hold |
18
|
58.26€ | Buy/Sell | 0.00€ | 2.99% |
Quest Diagnostics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Quest Diagnostics's EPS has fallen from $11.18 to $0.00 – a 100.00% decrease. Next year, analysts are expecting EPS to reach $9.04 – an increase of 100.00%. Over the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CRL Stock Forecast | Charles River Laboratories Int... | Outperform |
16
|
$221.61 | Buy/Sell | $229.97 | 21.84% |
| NTRA Stock Forecast | Natera | Buy |
7
|
$106.46 | Buy/Sell | $74.41 | 17.41% |
| BRKR Stock Forecast | Bruker | Outperform |
16
|
$75.07 | Buy/Sell | $73.64 | 14.56% |
.jpg)